Abstract
Two phase 2 studies of N-terminal tau–targeting antibody therapy fail to show clinical efficacy in progressive supranuclear palsy, despite evidence of target engagement.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
